Arbutus Biopharma Advances Clinical Trials and Strengthens Financial Position in Q3 2024
WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) has released its third-quarter 2024 financial results, showcasing significant progress in its clinical trials and a stable financial position. The company is …
Arbutus Biopharma Advances Clinical Trials and Strengthens Financial Position in Q3 2024 Read More